Abstract. Tumor suppressors are a group of important inverse regulators for carcinogenesis in human cancers including nasopharyngeal carcinoma (NPC). DOC-2/DAB2 interactive protein (DAB2IP) has been found to be a novel tumor suppressor in malignancies. However, the expression and biological function of DAB2IP in NPC have not been previously reported. This study found that the levels of DAB2IP were decreased in NPC tissues compared to non-cancerous nasopharyngeal epithelium tissues. In addition, downregulation of DAB2IP mRNA was confirmed by qRT-PCR in NPC cell lines as compared with a human immortalized nasopharyngeal epithelial cell line NP69. The reduced expression of DAB2IP was significantly correlated with lymph node metastasis and advanced clinical stage. DAB2IP low expressing NPC patients showed a notable reduced overall survival and disease-free survival. Functionally, DAB2IP restoration prohibited cell proliferation, colony formation, migration and invasion in both 5-8F and CNE-2 cells. Moreover, DAB2IP overexpression restrained the subcutaneous growth and lung metastasis of NPC cells in nude mice. Mechanically, DAB2IP overexpression repressed the activation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway and subsequently reduced the expression of its downstream targets including cyclin D1 and matrix metallopeptidase 7 (MMP7), which were identified as critical regulators for growth and metastasis of NPC. The Akt inhibitor MK-2206 showed similar effects to DAB2IP overexpression on growth and metastasis of 5-8F cells. Thus, DAB2IP suppresses growth and metastasis of NPC probably by targeting PI3K/Akt pathway.

Introduction

Nasopharyngeal carcinoma (NPC), which shows the highest morbidity in otorhinolaryngeal carcinoma, is one of the leading cause of cancer-related deaths all over the world (1). Although remarkable improvements have been achieved in the treatment of NPC, the prognosis for the NPC patients remains poor (2). Identifying novel molecules that are critical for the progression of NPC will bring new opportunity to find effective treatment options for NPC patients (3).

DAB2IP, a Ras GTPase-activating protein (4), exerts a critical role in cancer cell growth and metastasis as well as other aspects during tumor progression (5). Epigenetic silencing is the main cause of dysregulated expression of DAB2IP in human cancers (6). The expression of DAB2IP is silenced by promoter methylation and histone modification in prostate cancer (7,8). In bladder cancer, DAB2IP expression is suppressed by posttranscriptionally regulation of miR-92b (9). Furthermore, DAB2IP is recognized as a direct downstream target of miR-889 in esophageal squamous cell carcinomas (10). In prostate cancer, loss of DAB2IP facilitates the metastasis and epithelial-mesenchymal transition (EMT) process of cancer cells (11), and DAB2IP silencing inhibits androgen deprivation therapy-induced apoptosis via targeting STAT3 signaling (12). Furthermore, DAB2IP deficiency promotes the growth of renal cell cancer (RCC) and leads to the resistance of mTOR-targeted therapies in metastatic RCC (13,14). DAB2IP functions as a biomarker for prognosis prediction of colorectal cancer (CRC) and its loss promotes EMT and stem cell-like features in CRC cells (15,16). However, the expression status and function of DAB2IP in NPC remain poorly known.

In this study, we found that DAB2IP was decreased in NPC tissues and cell lines. Decreased level of DAB2IP was correlated with malignant clinical features and poor prognosis of NPC patients. DAB2IP restoration inhibited the growth and metastasis of NPC cells in vitro and in vivo. Importantly, DAB2IP exerted its tumor suppressive effects on the growth and metastasis of NPC probably by targeting PI3K/Akt pathway.

Materials and methods

Cell culture and transfection. NPC cell lines including CNE-1, CNE-2, 5-8F and 6-10B as well as a human immortalized nasopharyngeal epithelial cell line NP69 were from the Cell Bank of Chinese Academy of Sciences (Shanghai, China) and American Type Culture Collection (ATCC, Manassas, VA,
USA). All cells were cultured in DMEM medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (HyClone). Cell cultures were kept in cell incubators with humidified atmosphere and 5% CO2 at 37°C. Retroviral vector pMMP-DAB2IP was constructed by inserting the corresponding cDNA into pMMP. The retroviruses were packaged and transfected into CRC cells as previously described (17). Akt inhibitor MK-2206 (1 µM, Selleck Chemicals, Houston, TX, USA) was used to treat NPC cells following the manufacturer's instructions.

Clinical samples. Clinical specimens including 68 NPC tissues and 20 non-cancerous nasopharyngeal epithelial tissues were collected at Cangzhou Central Hospital. Twenty non-cancerous nasopharyngeal epithelial tissues obtained at tonsillectomies were included as normal controls. Tissue specimens were conserved in liquid nitrogen. All these clinical tissues were pathologically confirmed before being used for further experiments in this study. NPC patients who previously received radiotherapy or chemotherapy were excluded. The informed consent was obtained from each patient involved in this study. Approvals for experiments involving the patient samples was obtained from the Institutional Research Ethics Committee of Cangzhou Central Hospital.

Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). The total RNA from NPC tissues and cells were extracted with TRIzol (Invitrogen, Carlsbad, CA, USA). Reverse transcriptional reactions and PCR were performed with the Transcriptional First Strand cDNA (Applied Biosystems, Foster City, CA, USA). The total RNA from NPC tissues obtained from the Institutional Research Ethics Committee of Cangzhou Central Hospital. Twenty non-cancerous nasopharyngeal epithelial tissues obtained at tonsillectomies were included as normal controls. Tissue specimens were conserved in liquid nitrogen. All these clinical tissues were pathologically confirmed before being used for further experiments in this study. NPC patients who previously received radiotherapy or chemotherapy were excluded. The informed consent was obtained from each patient involved in this study. Approvals for experiments involving the patient samples was obtained from the Institutional Research Ethics Committee of Cangzhou Central Hospital.

Western blot analysis. Total protein lysates (30 µg) that were extracted from NPC tissues and cells with RIPA buffer were quantified with a BCA protein assay kit (Pierce, Bonn, Germany) and separated in 4-20% SDS-PAGE gels. After being separated on gels, protein samples were transferred to PVDF membranes at 4°C. The membranes were blocked with 5-10% milk/TBST and were incubated with DAB2IP (1:500; sc-365921, Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-AKT (1:2,000; #4060, Ser473; Cell Signaling Technology, Beverly, MA, USA), AKT (1:1,000; #4691, Cell Signaling Technology), cyclin D1 (1:1,000; #2978, Cell Signaling Technology), MMP7 (1:800; 10374-2-AP, Proteintech, Rosemont, IL, USA) or GAPDH (1:1,000; sc-32233, Santa Cruz Biotechnology) primary antibodies at 4°C overnight. Then, the membranes were incubated with secondary antibodies (1:5,000; #7074/7076, Cell Signaling Technology). The protein signals on the membranes were detected using ECL reagents (Santa Cruz Biotechnology) and semi-quantified by ImageJ software (1.46; National Institutes of Health, Bethesda, MD, USA).

Proliferation assay. NPC cells that were treated with empty vector or DAB2IP were seeded into 96-well plates (1.5x10^3 cells per well). CCK-8 cell viability assay were performed as previously reported (18). For the colony formation assay, 2,000 NPC cells were seeded on 6-well plates, and 14 to 21 days after cell seeding, cell colonies with crystal violet staining were counted.

Transwell assay. Transwell inserts were employed to evaluate the migratory and invasive ability of NPC cells. NPC cells (1x10^5) were resuspended in serum-free DMEM medium and were seeded in the upper chamber. To induce the migration and invasion of NPC cells, the lower chambers were filled with 600 µl DMEM supplemented with 20% FBS. Forty-eight hours after cell seeding, NPC cells migrated or invaded through the membranes (for invasion assay, the membrane were covered with 70 µl Matrigel) were stained with crystal violet for cell counting under the microscope.

Subcutaneous implantation and tail vein injection assays. The in vivo growth ability of NPC cells was examined using the subcutaneous implantation nude mouse model using female BALB/c nude mice (4-5 weeks). NPC cells (1x10^6) transfected with control vector or DAB2IP were subcutaneously injected into the left flank. During 24 days, the subcutaneous tumors were subjected to volume measurements and finally resected. To evaluate the in vivo metastatic ability of NPC cells, tail vein injection model was performed in the nude mice. NPC cells (1x10^5) transfected with control vector or DAB2IP were intravenously injected through the tail vein. Six weeks later, the mice were sacrificed by cervical dislocation under anesthesia. The lungs of nude mice were fixed with 10% formalin and paraffin-embedded, and were then subjected to H&E staining for potential lung metastatic lesions. All animal experiments in this study were approved by the Animal Care Committee of Cangzhou Central Hospital.

Statistical analysis. The data in this study are shown as mean ± SEM. Statistical analysis including Student's t-test, Chi-square test, ANOVA, Kaplan-Meier analysis and log-rank test were performed using the GraphPad Prism 5 software (GraphPad Software, Inc, San Diego, CA, USA). P-value <0.05 was considered to be statistically significant.

Results

DAB2IP expression was decreased in NPC tissues and cells. To understand the expression status of DAB2IP in NPC, we extracted total proteins from the NPC tissues and non-cancerous tissues. The results of immunoblotting showed that the levels of DAB2IP protein were significantly decreased in NPC tissues compared to non-cancerous nasopharyngeal
epithelium tissues (P<0.05, Fig. 1A). In addition, qRT-PCR was performed to detect the expression differences of DAB2IP mRNA in 20 paired NPC and normal tissues. DAB2IP mRNA was also notably underexpressed in NPC specimens (P<0.05, Fig. 1B). Furthermore, we examined the expression of DAB2IP mRNA in NPC cell lines. Compared with NP69 cells, the expressions of DAB2IP mRNA was prominently lower in all NPC cell lines including CNE-1, CNE-2, 5-8F, and 6-10B (P<0.05, respectively, Fig. 1C). Thus, downregulation of DAB2IP was confirmed in NPC.

**Downregulation of DAB2IP correlates with unfavorable clinicopathological features and poor prognosis of NPC patients.** After confirming the decreased expression of DAB2IP in NPC, we evaluated the clinical significance of DAB2IP in NPC patients. We divided the NPC patients into two groups (DAB2IP high or low group) based on the cutoff value which was defined as the median value of DAB2IP protein level. As shown in Table I, DAB2IP low expression was associated with advanced clinical stage (P=0.011) and lymph node metastasis (P=0.006). Furthermore, DAB2IP low expressing NPC patients showed a notable reduced 5-year overall survival and disease-free survival (P=0.045 and P=0.032, respectively, Fig. 2). These data indicate that DAB2IP is a promising prognostic marker for NPC patients.

**DAB2IP restrains the proliferation, migration and invasion of NPC cells.** Since the levels of DAB2IP mRNA were relatively lower in 5-8F and CNE-2 cells, DAB2IP expression was

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n</th>
<th>Low (n=34)</th>
<th>High (n=34)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>38</td>
<td>20</td>
<td>18</td>
<td>0.625</td>
</tr>
<tr>
<td>≥50</td>
<td>30</td>
<td>14</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>45</td>
<td>21</td>
<td>24</td>
<td>0.442</td>
</tr>
<tr>
<td>Female</td>
<td>23</td>
<td>13</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td>0.011*</td>
</tr>
<tr>
<td>I+II</td>
<td>12</td>
<td>2</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>III+IV</td>
<td>56</td>
<td>32</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td>0.006*</td>
</tr>
<tr>
<td>No</td>
<td>18</td>
<td>4</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>50</td>
<td>30</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td>0.132</td>
</tr>
<tr>
<td>No</td>
<td>60</td>
<td>28</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

*Statistically significant.
restored by retroviruses infection in these two cells (Fig. 3A). CCK-8 assays revealed that overexpression of DAB2IP significantly inhibited the proliferation of both 5-8F and CNE-2 cells (P<0.05, respectively, Fig. 3B). In addition, the number of colonies was notably reduced after DAB2IP overexpression in NPC cells (P<0.05, respectively, Fig. 3C). Transwell assays showed that DAB2IP overexpression obviously decreased the number of migrated and invaded cells (P<0.05, respectively, Fig. 4). Thus, DAB2IP suppresses NPC cell proliferation, migration and invasion in vitro.

**DAB2IP reduces growth and metastasis of NPC cells in nude mice.** To further confirm the functional influence of DAB2IP on NPC cells, we performed subcutaneous tumor formation and lung metastasis experiments to test whether DAB2IP affected growth and metastasis of NPC cells. Overexpression of DAB2IP obviously decreased the subcutaneous growth of NPC in nude mice as suggested by tumor growth curves (P<0.05, Fig. 5A). In addition, lung metastasis experiments showed that DAB2IP notably reduced the number of metastatic nodules in the lungs of nude mice (P<0.05, Fig. 5B). Altogether, DAB2IP functions as a tumor suppressor in NPC.

**PI3K/Akt pathway is a potential downstream target of DAB2IP in NPC cells.** After determining the biological functions of DAB2IP in NPC cells, we examined the underlying...
Figure 4. DAB2IP overexpression inhibits the migration and invasion of NPC cells. (A) Transwell assays confirmed that DAB2IP overexpression significantly reduced the migration and invasion of 5-8F cells. n=3 replicates with similar results, *P<0.05 by t-test. (B) The number of migrated and invaded cells was prominently reduced after DAB2IP overexpression in CNE-2 cells. n=3 replicates with similar results, *P<0.05 by t-test.

Figure 5. DAB2IP inhibits growth and lung metastasis of NPC in nude mice. (A) 5-8F cells that were infected with control vector or DAB2IP retroviruses were implanted into nude mice via subcutaneous injection. Tumor growth curves revealed that DAB2IP overexpression significantly inhibited the growth of NPC in vivo. n=5, *P<0.05 by ANOVA. Scale bar, 1 cm. (B) 5-8F cells that were infected with control vector or DAB2IP retroviruses were intravenously injected into nude mice via tail vein. H&E staining revealed that DAB2IP overexpression significantly reduced lung metastases of 5-8F cells (original magnification, ×100). n=5, *P<0.05 by t-test. M, metastases; N, normal lung.
DAB2IP regulates PI3K/Akt pathway in NPC cells. The activity of PI3K/Akt pathway and the levels of its downstream proteins, cyclin D1 and MMP7, after DAB2IP overexpression were examined by western blot analysis in both 5-8F and CNE-2 cells. DAB2IP overexpression prohibited the activation of PI3K/Akt pathway with reduced expression of phosphorylated Akt and downregulated the levels of cyclin D1 and MMP7 in NPC cells.

Figure 6. DAB2IP regulates the activation of PI3K/Akt pathway in NPC cells. The activity of PI3K/Akt pathway and the levels of its downstream proteins, cyclin D1 and MMP7, after DAB2IP overexpression were examined by western blot analysis in both 5-8F and CNE-2 cells. DAB2IP overexpression prohibited the activation of PI3K/Akt pathway with reduced expression of phosphorylated Akt and downregulated the levels of cyclin D1 and MMP7 in NPC cells.

Figure 7 Akt inhibitor MK-2206 inhibits the proliferation and metastasis of 5-8F cells. (A) 5-8F cells that were treated with vehicle or MK-2206 (1 µM) were confirmed by western blotting for p-Akt, Akt, cyclin D1 and MMP7 expression. (B) CCK-8 assays confirmed that MK-2206 treatment obviously inhibited proliferation of 5-8F cells. n=3 replicates with similar results, *P<0.05 by ANOVA. (C) The relative colony numbers were notably reduced after MK-2206 treatment in 5-8F cells. n=3 replicates with similar results, *P<0.05 by t-test. (D) Transwell assays indicated that MK-2206 treatment prominently restrained the migration and invasion of 5-8F cells. n=3 replicates with similar results, *P<0.05 by t-test.
5-8F cells (P<0.05, respectively, Fig. 7B-D). Here, we suggest that DAB2IP suppresses the progression of NPC possibly by targeting the PI3K/Akt pathway.

Discussion

Loss or downregulation of tumor suppressors have been found to be closely associated with cancer development and progression (21,22). Among these tumor suppressors, DAB2IP is a newly identified tumor suppressor closely related with human cancers (5). In this study, we confirmed for the first time that DAB2IP expression was significantly reduced in NPC tissues and cell lines. Decreased DAB2IP level was associated with unfavorable clinicopathological features and poor prognosis of NPC patients. In vitro functional assays showed that DAB2IP could restrain proliferation, migration and invasion of NPC cells. In vivo experiments also confirmed that DAB2IP inhibited the growth and metastasis of NPC cells in nude mice. These data indicate that DAB2IP plays a tumor suppressive role in NPC by inhibiting tumor growth and metastasis.

DAB2IP was identified as a new member of the Ras GTPase-activation protein family (5). DAB2IP regulates cell proliferation, apoptosis, migration and invasion via modulating various signaling pathways by directly interacting with DAB2 (5). Previous studies showed DAB2IP exerts critical roles in human cancers including prostate cancer (6,8,12), CRC (15,16) and RCC (13,14). PI3K/Akt pathway has been reported to play an important role in the initiation and progression of NPC (23,24). Notably, DAB2IP suppression of the activation of PI3K/Akt pathway is reported in prostate cancer (25), bladder cancer (26), but not in NPC. Here, we revealed that DAB2IP overexpression blocked that activation of PI3K/Akt pathway with reduced level of phosphorylated Akt in NPC cells. Accordingly, the levels of cyclin D1 (27) and MMP7 (28), downstream targets of PI3K/Akt pathway, were downregulated by DAB2IP restoration. cyclin D1, a regulator of cell cycle progression, promotes NPC cell proliferation via promoting G1(1)-phase transition (29). Moreover, MMP7 has been reported to promote invasion of NPC cells (20). A previous study suggested that Wnt signaling facilitates cell proliferation via cyclin D1 and promoted invasion by MMP7 in NPC (20). The expression of PI3K/Akt pathway molecules, such as p-Akt, cyclin D1 and MMP7, were upregulated in NPC tissues compared to normal tissues as previously reported (30-32). Furthermore, MK-2206, the Akt inhibitor (33), blocked the PI3K/Akt pathway and suppressed the growth and metastasis of NPC cells in vitro, which was consistent with a previous study (34). Thus, we suggest that DAB2IP represses growth and metastasis of NPC by inhibiting PI3K/Akt pathway and subsequently suppressing cyclin D1 and MMP7 expression. DAB2IP expression is frequently impaired by methylation in cancer (35). Thus, the methylation status of DAB2IP in NPC is worth investigation in the future.

Collectively, DAB2IP expression was decreased in NPC tissues and cells. DAB2IP inhibited the progression of NPC by suppressing the proliferation and metastasis of NPC cells both in vitro and in vivo. Mechanically, PI3K/Akt was identified to be the downstream target of DAB2IP in NPC cells. DAB2IP potentially acts as a prognostic predictor and a drug-target for NPC patients.

Acknowledgements

The authors thank all the patients who participated in this study.

References


